Author: Septerna, Inc.

Posted Date:

May 5, 2026

Septerna to Present at Bank of America Securities Health Care Conference

Septerna, Inc.

May 5, 2026
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

Septerna, Inc.

April 13, 2026
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Septerna, Inc.

March 9, 2026
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

Septerna, Inc.

March 1, 2026
Septerna to Present at TD Cowen 46th Annual Health Care Conference

Septerna, Inc.

February 24, 2026
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Septerna, Inc.

February 10, 2026
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting

Septerna, Inc.

February 10, 2026